Woodcliff Lake, NJ, United States of America

Yiwen Li

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 7 CIPO patents and 4 EPO patents. Top assignees: Eli Lilly and Company, Zymeworks Inc., Innovent Biologics (Suzhou) Co., Ltd.. Active years: 2019-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yiwen Li. Retrieved from https://idiyas.com/inventor/yiwen-li-hfrswdwu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 85.7

CIPO Patents = 7 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Woodcliff Lake, NJ (US) (2019 - 2022)
Woodcliff, NJ (US) (2022 - 2024)

Company Filing History:

7 out of 4,517

Eli Lilly and Company

Innovent Biologics (Suzhou) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2019-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12037406 - Anti-CD137 antibodies for combination with anti-PD-L1 antibodies (2024-07-16),

2. 11352424 - Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies (2022-06-07),

3. 11351251 - Anti-PD-L1-anti-TIM-3 bispecific antibodies (2022-06-07),

4. 11203640 - Checkpoint inhibitor bispecific antibodies (2021-12-21),

5. 10279034 - Anti-PD-L1-anti-TIM-3 bispecific antibodies (2019-05-07),

6. 10253096 - Anti-Tim-3 antibodies (2019-04-09),

7. 10214586 - PD-L1 antibodies (2019-02-26),

Title: Yiwen Li: Innovator in Cancer Therapeutics

Introduction

Yiwen Li is a prominent inventor based in the United States, recognized for her contributions to the field of cancer therapeutics. With a focus on innovative antibody treatments, she has made significant strides in developing therapies that target specific cancer pathways.

Latest Patents

Although Yiwen Li currently holds no patents, her latest inventions include groundbreaking concepts such as Anti-CD137 Antibodies for Combination with Anti-PD-L1 Antibodies. This invention relates to antibodies that bind to human CD137 and display agonist activity, potentially useful for treating solid and hematological tumors in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation. Another notable invention is the Checkpoint Inhibitor Bispecific Antibodies, which are heterodimeric antibodies that bind human PD-L1 and human PD-1, offering potential treatment options for cancer alongside chemotherapy and other cancer therapeutics.

Career Highlights

Throughout her career, Yiwen Li has worked with esteemed organizations, including Eli Lilly and Company and Zymeworks BC Inc. Her experience in these companies has allowed her to contribute to the advancement of cancer treatment methodologies.

Collaborations

Yiwen Li's collaborations with leading pharmaceutical companies have been instrumental in her research and development efforts. By working alongside experts in the field, she has been able to enhance the efficacy of her

Profile summary based on public USPTO records.